The effects of ovarian cancer cell-derived exosomes on vascular endothelial growth factor expression in endothelial cells.
Exo-OVCAR-3
cancer cell-derived exosomes
ovarian cancer
vascular endothelial growth factor
Journal
EXCLI journal
ISSN: 1611-2156
Titre abrégé: EXCLI J
Pays: Germany
ID NLM: 101299402
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
09
2019
accepted:
08
10
2019
entrez:
25
10
2019
pubmed:
28
10
2019
medline:
28
10
2019
Statut:
epublish
Résumé
Ovarian carcinoma is considered as a major clinical challenge worldwide. Exosomes, nano-sized intraluminal vesicles of multivesicular bodies, are secreted by most types of cells and play an important role in intercellular communication. Cancer cell-derived exosomes can develop cancer progression and metastasis by manipulating the local and distant biological environments. Angiogenesis is an important contributor to tumor progression. Vascular endothelial growth factor (VEGF) is the most potent pro-angiogenic protein and induces proliferation, sprouting, and vessel formation by endothelial cells. In this study, exosomes derived from ovarian epithelial cancer cells OVACAR-3 (exo-OVCAR-3) were successfully isolated and characterized by scanning electron microscopy in terms of size and morphology. Cellular internalization of exosomes labeled with PKH fluorescent dye was monitored by a fluorescence microscope. Our results elucidated that exosomes treatment (100 µg/ml) had a promoting effect on VEGF expression and secretion in endothelial cells. Furthermore, we demonstrated that exo-OVCAR-3 caused an increase in the proliferation and migration rate of endothelial cells. It seems that inducing VEGF by exo-OVCAR-3 can influence the vascular behavior of endothelial cells
Identifiants
pubmed: 31645849
doi: 10.17179/excli2019-1800
pii: 2019-1800
pii: Doc899
pmc: PMC6806135
doi:
Types de publication
Journal Article
Langues
eng
Pagination
899-907Informations de copyright
Copyright © 2019 Ghorbanian et al.
Références
J Biol Chem. 1999 Oct 22;274(43):31047-54
pubmed: 10521504
Dev Cell. 2010 Jun 15;18(6):884-901
pubmed: 20627072
Neurobiol Aging. 2014 Aug;35(8):1792-800
pubmed: 24650793
J Proteomics. 2013 Mar 27;80:171-82
pubmed: 23333927
Mol Cancer. 2019 Mar 30;18(1):67
pubmed: 30927930
Clin Biochem. 2009 Aug;42(12):1291-9
pubmed: 19439162
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell Oncol (Dordr). 2017 Oct;40(5):457-470
pubmed: 28741069
Oncotarget. 2017 May 30;8(22):36137-36148
pubmed: 28410224
Nat Rev Mol Cell Biol. 2006 May;7(5):359-71
pubmed: 16633338
J Clin Oncol. 2005 Feb 10;23(5):1011-27
pubmed: 15585754
J Clin Invest. 2013 Aug;123(8):3190-200
pubmed: 23908119
Nat Rev Cancer. 2006 May;6(5):392-401
pubmed: 16572188
Handb Exp Pharmacol. 2007;(180):263-83
pubmed: 17554513
Cancer Invest. 2008 Feb;26(1):104-8
pubmed: 18181052
PLoS One. 2013 Dec 31;8(12):e84256
pubmed: 24391924
Int J Womens Health. 2017 Dec 15;9:913-924
pubmed: 29290694
Oncotarget. 2015 Jan 20;6(2):715-31
pubmed: 25596732
Curr Top Microbiol Immunol. 1999;237:97-132
pubmed: 9893348
Ann Oncol. 2013 Dec;24 Suppl 10:x7-15
pubmed: 24265410
Am J Cancer Res. 2011;1(1):98-110
pubmed: 21969178
Clin Cancer Res. 2001 Feb;7(2):435-42
pubmed: 11234901
Curr Mol Med. 2013 Jan;13(1):58-67
pubmed: 22834836
Int J Cancer. 2006 Oct 1;119(7):1519-29
pubmed: 16671089
Front Oncol. 2018 Apr 19;8:117
pubmed: 29725585
Nat Med. 2003 Jun;9(6):669-76
pubmed: 12778165
Tumour Biol. 2016 Sep;37(9):12169-12180
pubmed: 27220495
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Oncologist. 2000;5 Suppl 1:3-10
pubmed: 10804084
Clin Cancer Res. 2013 Mar 1;19(5):961-8
pubmed: 23307860
Cancer Res. 1996 Sep 1;56(17):4032-9
pubmed: 8752175
Oncotarget. 2017 Oct 31;8(61):104687-104703
pubmed: 29262670
Cell Mol Biol (Noisy-le-grand). 2016 Jun 30;62(7):74-9
pubmed: 27453276
Cancer Res. 2005 May 15;65(10):3967-79
pubmed: 15899784